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INTRODUCTION
Globally, obesity has more than doubled since 1980,
whereas childhood obesity tripled in the same period of time
(1, 2). In the following years, obese prevalence will increase
as overweight and obese children (for 2 to 12 years) and
adolescents (from 12 to 16 or 18 years) are likely to remain
obese in the adulthood. Unfortunately, this suggests that
health professionals will, in the near future, provide daily
health-care services to the obese patients. Morbidity and
mortality increase with obesity, where greater incidence of
cardiovascular diseases, diabetes, hyperlipidemia, variety of
cancers is observed (3, 4). Accordingly, obese patients are
multi morbid, and require multiple drug therapies. 
Obese patients have significant changes in body compo-
sition that contribute to alterations in the pharmacokinetic
(PK) profile of a drug. When studying PK of a drug in pedi-
atric obese patients, at least two simultaneous factors are
affecting it: patient’s age and obesity (5, 6).  Ethical reasons
limit the involvement of the pediatric subjects in the clinical
trials, and, at the same time, obesity is neglected as a factor
of variability during drug development. Additionally, exist-
ing studies are limited by the poor design and insufficient
sample size (7). Therefore, data on drugs’ PK in this popula-
tion of patients are scarce, incomplete and inconclusive.
However, certain PK changesmaybeof a clinical importance,
consequently requiring the adjustment of the drug’s dosing
regimen to individual patient needs (7-12). Hence, adequate
drug dosing to pediatric obese patients represents a major
challenge for the health-care professionals. 
ASSESSMENT OF BODY COMPOSITION IN
OBESE PEDIATRIC PATIENTS
Previous studies have shown that obese children are
taller, their total body weight (TBW) is increased due to
increased, primarily, fat mass, and, to lesser extent increase
in body water, lean mass in comparison to their normal-
body-weight controls (13). Traditionally, body fatness has
been estimated from the measurements of the skin fold
thickness. The accuracy of this approach is a major concern
because of poor reproducibility, and the inclusion of only
Abstract
Since the incidence of obesity continues to increase globally, this source of disposition vari-
ability remains a significant issue for clinicians. The prevalence of overweight and
obesechildren has increased worldwide, causing substantial concern over proper therapeu-
tic dosing in this population. Pharmacotherapy in these patients represents a major chal-
lenge in the clinical practice, because obese patients are, often, excluded from the clinical
trials. Consequently, data on drugs’ pharmacokinetics (PK) in this population of patients are
scarce, incomplete and/or inconclusive. It is previously observed that different degrees of
obesity may change the PK profile of drug. Consequently, there is a need for the descrip-
tors of size of the organism that best describes the changes in the composition of the organ-
ism in obese patients, and the one that best predicts key PK parameters that define dosage
regimen. Changes in PK parameters of certain drugs are clinically important in the obese
children and adolescent patients, requiring changes in usual dosage regimen.
Key words
variability, children, body mass index
Klju~ne re~i
varijabilnost, deca, indeks telesne mase
Correspondence to: 
assist. prof. Katarina Vučićević, PhD
Department of Pharmacokinetics and
Clinical Pharmacy, Faculty of Pharmacy
- University of Belgrade
Vojvode Stepe 450. 11221 Belgrade,
Serbia
phone: +381-11-3951-373
e-mail: kacav@pharmacy.bg.ac.rs
medicinska revija
medical review
Vučićević K. et al n MD-Medical Data 2016;8(3): 149-153
UDK:615.015-053.2
613.25-053.2
COBISS.SR-ID 226160396
MD MEDICAL DATA / Vol.8 NO 3 / Septembar-September 2016.150
Revijski članci/ Review articles
few regional body sites for the measurement represents a
major limitation. Consequently, height and weight-based
parameters, adjusted for the age and gender, are the most
practical descriptors of body size and its composition (14).
Pediatric dosing recommendations are, for the majority
of medications, weight-based reflecting the use of TBW (15).
However, using obese child’s TBW for calculating the dose
according to the recommended milligrams per kilogram may
not be justifiable, as TBW does not show proportionality
with body structure. No supreme descriptor for PK-based
drug dosing in obese exists. However, different body size
descriptors for adults and/or pediatrics have been used in PK
studies, such as: body mass index (BMI), body surface area
(BSA), ideal body weight (IBW), percent of ideal body
weight (%IBW), lean body weight (LBW), adjusted body
weight (ABW), normal fat mass (NFM) (16-19). In pediatric
population, the assessment and the interpretation of such
descriptors may be different comparing to the adults.
Body Mass Index (BMI) is the parameter used in inter-
national classification of obesity, which represents the ratio
between TBW in kilograms and the square of height in
meters. Unlike adult population, BMI in children and ado-
lescents is age and gender dependent. Therefore, overweight
and obesity classificationin adults does not apply to pediatric
population. World Health Organization (WHO) provides the
reference charts by BMI-for-age indicators for boys and
girls from 5 to 19 years (1). Hence, 23 kg/m2 is healthy
weight in adults while a 10-year-old boy with the same BMI
would be in obese category since z-scores for his BMI
exceeds 2 standard deviations for a median child’s BMI for
that age and gender, given by specific WHO growth stan-
dards (1). It is shown that BMI represents reliable indicator
of body fatness for most children and adolescents (2), how-
ever it does not measure directly fat tissue. Fat mass is main-
ly concentrated in abdominal region, and it represents 30-
50% of children’s TBW(13). Additionally, increased hydra-
tion of lean mass due to increase in extracellular fluid was
observed (13, 20). This indicates that the use of BMI as
ascalar parameter for drug dosing is limited, since pati ents
with higher content of extracellular water may receivethe
same dose as patients with increased fat content. For chil-
dren under 5 years, obesity is defined if child’s weight for
height is greater than three standard deviations to the res -
ponding median values given by WHO growth standards (1).
Body Surface Area (BSA) takes into account person’s
TBW and height using specific equations (9, 21). From the
physiological point of view, this parameter may be suitable
for drugs’ dosing since it correlates reasonably well with
basal metabolism, estimated glomerular filtration rate
(eGFR), blood volume i.e. drug’s PK characteristics (9). Its
use has been established for dosing many chemotherapeutic
agents; though nowadays the justification of its use is ques-
tionable. Nevertheless, the equation for calculating BSA in
obese patients is not well-defined. Although current recom-
mendations for obese adults suggest using TBW for the BSA
calculation when dosing cytotoxic chemotherapy drugs is
BSA-based (22). BSA does not considerate child's gender
and age, and its use in drug dosing to obese pediatric patients
is open for future research (9, 23). Currently available data
suggest that clearance of methotrexate, etoposide, tenipo-
side, and cytarabine normalized to BSA did not differ
between the weight stratified groups of patients (24).
Ideal Body Weight (IBW) is used to determine the opti-
mal body weight according to the gender and height. Percent
Ideal Body Weight (%IBW) quantitatively describes the
TBW inrelation to IBW. Adult patients whose TBW is 30%
over their IBW are considered obese, however there are no
data confirming that same threshold may be acceptable in
children and adolescents. Assessment of IBW for pediatrics
is possible using growth charts, such as the ones proposed by
WHO(1) or Center for Disease Control and Prevention (2)
that consist of a series of percentile curves that illustrate the
distribution of selected body measurements in pediatrics.
Using IBW for drugs dosing would result in administrating
the same dose to all pediatric patients same age, gender and
height regardless thebody composition. 
Lean Body Weight (LBW) is primarily composed of
muscle, extracellular fluid, skeletal system, andvital organs.
Itis a use ful parameter in adult obese patientswhen estimat-
ing PK parameters and dosage regimen, since almost in
whole elimination processes (metabolism and excretion)
take place within lean tissues (25). In children, similar to
adults, relationships between estimated LBM, extracellular
fluid and TBW are defined. Therefore, drug dosage in chil-
dren may also be based on the estimated LBM rather than
TBW where proven its the use in adults (26). It has great
importance in loading and maintenance dose of some anes-
thetic agents (27). 
Adjusted Body Weight (ABW)is introduced in order to
optimize the dosage regimen of aminoglycoside antibiotics
in adults, and it can be calculated as IBW+0.4(TBW-IBW)
(28, 29). 
PHARMACOKINETIC CHANGES IN OBESE 
CHILDREN AND ADOLESCENT PATIENTS
PK driven dosing is based on the PK parameters’ values
and target drug concentrations. These parameters adequate-
ly represent processes of drug absorption, distribution,
metabolism and excretion, which are dependent on body
size, maturation, and organs’ functions involved in these
process in pediatric patients (15, 18). Anderson et al. illustrat-
ed that more than 80% of the observed variability in drug
clearance (CL) can be explained by allometry principles and
maturation process (18). Given that overweight children tend
to have earlier puberty maturation, and they are, in general,
more mature (30), it emphasizes the need to take into account
this factor when considering the PK changes in obese chil-
dren. 
Physiological/pathophysiological changes in obese
patients may cause minor or major changes in the values of
PK parameters that require considerations for changing the
usual drug dosage regimen. Drugs’ dosing based on TBW or
BSA is not completely acceptable to obese patients as the
structural and functional aspects of an organism are not sim-
ilar in obese and non-obese pediatric patients. Structural
aspects of the organism are defined by volume of distribu-
tion (Vd), while the functional is correlated with CL which
reflects intrinsic capacity of the various organsand contribu-
tion of their perfusion to clear the drug (6, 12, 17). Since data
of the effect of obesity in pediatric population of patients are
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scarce, extrapolations from obese adults, in spite of PK dif-
ferences between pediatric and adult population, might be
sometimes useful. 
Minor changes in oral, subcutaneous or intramuscular
drug absorption are observed; however the clinical impor-
tance of these variations is doubtful (31).
Distribution of drugs is affected primarily by the body
composition, whereas regional blood flow, and drug affinity
for tissue and plasma protein binding have minor impor-
tance(10). The amount of fat mass normally changes through-
out the childhood. As previously mentioned, the increase of
TBW, absolute and relative fat content, lean mass and its
hydration are observed in obese children (13, 20). The pres-
ence of large amounts of fat can significantly affect Vd of
the drug. Results of studies in adult population show that Vd
is not always directly correlated with the degree of
hydrophility or lipophility(11, 17). The physiologic determi-
nates of Vd are the actual blood volume (Vblood) and the
volumes of the body tissues and organs (Vtissues) where
drug distributes, taking into account unbound drug fraction
(f), according to the following equation(29):
Therefore, absolute amount of adipose tissue and the
binding of drug in the tissue itself will determine how much
obesity will affect drug’s Vd. If the drug shows great affini-
ty for adipose tissue, f in adipose tissue will be small, and a
large amount of drug will accumulate in that tissue. Drugs
with low and moderate lipophilic characteristics have limit-
ed distribution into excess fat tissue, so for hydrophilic
drugs dosing on LBW or IBW might be straightforward. Vd
of lipophilic drugs in obese is expected to increase due to
drug’s distribution into adipose tissue. However, increa sed
TBW in obese is not accounted only for fat tissue, thus Vd
of lipophilic drugs, as well, is variable in obese adults (10, 32,
33). In addition, most drugs are not purely hydro- or
lipophilic, so their distribution is rather between these
extremes. Similar patterns may be also applied to obese chil-
dren and adolescents. For instance, results reported by Rose
et al. showed that dosing of succinylcholine, hydrophilic
anesthetic drug, should be based on TBW (34), and not on
LBW as previously reported (35). In dosing succinylcholine,
changes in PK parameters do not play major role, but
increased pseudocholinesterase activity (34). PK analysis
performed on the measured tobramicin concentrations, con-
firmed, as expected, that Vd/TBW was significantly lower in
obese children in comparison to non-obese children due to
the physico-chemical characteristic of the drug and body
composition in obesity (36, 37). ABW was used to normalize
the values of Vd in obese patients where TBW exceedsa cer-
tain percentage ofIBW (28). Amino glyco si deantibiotics are
relatively polar molecules with good water solubility.
Therefore, they do not distribute in adipose tissue to any sig-
nificant extent. However, in obese patients, Vd for amino-
glycosides increases on account of the additional extracellu-
lar fluid contained in adipose tissue. The reason why amino-
glycosides’ Vd is affected by this relatively small amount of
additional extracellular fluid in adipose tissue lays in its rel-
atively small Vd of 0.26 L/kg. For other hydrosoluble drugs
with larger Vd, the additional extracellular fluid in adipose
tissue may not be a significant factor (29). Then again, great
number of studies confirms that changes in body composi-
tion in obese children and adolescents affect drug’s extent of
distribution (6, 7, 11, 12, 31). Changes in Vd affect initial drug
concentration following the administration of initial (single)
dose, maximal drug concentration, and drug’s half-life.
Metabolism undergoes variations in obese patients
through changes in the activities of enzymes involved in I
and/or II phase of metabolism (10, 38, 39). There are limiting
and not consisting results on the alteration of drugs’ hepatic
clearance (CLH) in obese pediatrics (7, 31). 
Excretion. Results of studies indicate non-uniform
changes in the processes of glomerular filtration, tubular
secretion and reabsorption, and consequently in the values
of renal clearance (CLR) of drugs in obese patients. If a drug
is predominantly eliminated via kidneys, its CLR is correlat-
ed with eGFR, which is, in pediatrics, calculated using
Schwartz method (40). However, it has not been validated in
obese pediatrics. In obese adults, creatinine clearance
(CLCR) may be calculated using Salazar-Corcoran formula
based on TBW, or Cockroft-Gault formula using LBW or
IBW (41, 42). In adolescent patients it has been showed that
eGFR were significantly lower in obese and/or overweight
than lean patients. A significant positive correlation was
found between eGFR and BMI in obese children age7-16
years (43). Hence, the effect of obesity on renal excretion
remains open for further research. 
Estimation of initial dose (Di) is based on value of Vd.
This parameter has great importance when rapid achieve-
ment of desired levels is needed in order to attain drug
effect. Vd can be expressed as an absolute value in liters or
normalized to TBW or IBW. If there is a difference in the
distribution coefficient values in obese patients and normal
body weight, it is apparent that the drug distributes to an
addi ti onal body weight. If no difference is observed, the
drug shows the distribution into adipose tissue. In that sce-
nario the calculation of Di is based on TBW. If the absolute
value of Vd increases in obese individual, a distribution
coefficient value is lower. This scenario indicates an incom-
plete distribution of the extra fat, and IBW or LBW should
be used (6, 7, 10, 12, 17, 31-33). Maintenance dose rate (given
dose per dosing interval, Do/τ) is based on total drug’s CL
(sum of CLR and CLH). There is no consensus which body
descriptor gives best prediction of CL, but it is clear that CL
does not increase proportionally with TBW. According to
Green and Duffull, LBW is the best descriptor of drug’s CL
(16).
CONCLUSIONS
PK changes in obese pediatric patients have clinical sig-
nificance affecting theefficacy and safety of the medicines.
In order to achieve optimal pharmacotherapy there is a need-
to adjust dosage regimen in obese children. Unfortunately,
the results from clinical trials are lacking due to ethical rea-
sons as well as from the fact that different stages of obesity
may cause different effect of drugs’ disposition. Previously
published manuscripts have shown that there is no single
body size descriptor, which describes the values of pharma-
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co kinetic parameters in these patients. In considering the
extrapolation of the results of performed studies to a specif-
ic patient, it is vital to critically appraise the study design,
and ensure the whether the patient fits the characteristics of
the population included in the study (e.g. age, range of BW,
%IBW, BMI). Apart from PK changes, differences in PD in
obese children and adolescents could be present and should
be also taken into account when dosing.Therefore, health-
care professionals have to observe obesity as a complex
source of variability in drug’s profile, and to consider the
need to adjust dosing regimen based on recommendations (if
available), patient’s degree of obesity, alterations in PK
processes, drug dosing in obese adults, and the available
results of the clinical studies in pediatrics. 
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Sažetak
Obzirom da se globalno uočava kontinuiran porast incidence gojaznih osoba, gojaznost
kao faktor varijabilnosti u dispoziciji leka postaje vrlo značajan aspekt razmatranja za
kliničare. Prevalenca dece sa prekomernom telesnom masom i gojazne dece se povećava
u svetu, dovodeći do nedoumica u pogledu pravilnog doziranja lekova u ovoj populaciji.
Farmakoterapija ovih pacijenata predstavlja veliki izazov u kliničkoj praksi, jer su gojazne
osobe, često isključene iz kliničkih ispitivanja. Stoga, podaci o farmakokinetici (FK) leko-
va u ovoj populaciji pacijenata su često oskudni, nepotpuni i/ili nisu utemeljeni na jakim
dokazima. Primecéno je da različiti stepen gojaznosti može promeniti FK profil leka.
Shodno tome, postoji potreba za deskriptorima veličine organizma koji najbolje opisuju
promene u sastavu organizma kod gojaznih pacijenata, ali i definisati onaj koji najbolje
predviđa vrednosti ključnih parametara FK koji definišu režim doziranja. Promene u FK
parametrima određenih lekovakod gojazne dece i adolescenata imaju klinički značaj, što
zahteva korekcije uobičajenih režima doziranja.
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